ArticleOncology reports2025
Deuterium-depleted water inhibits the malignant progression of colorectal cancer cells by modulating oxidative stress.
Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Knockdown of CCT2 inhibits the malignant progression of hepatocellular carcinoma cells by impairing STAT3 activation.Oncology reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most common types of cancer worldwide. Alternative therapy has been widely used in CRC treatment, with deuterium-depleted water (DDW) demonstrating promising anticancer effects in a number of cancer types. The aim of the present study was to assess the anticancer effects of DDW in CRC cells and the possible mechanism involved. HT-29 and DLD-1 cells were cultured in conditioned medium prepared with DDW. Cell malignant behaviors were assessed using EdU, colony formation, tumor-sphere formation, wound-healing and Transwell assays. Stemness-related proteins, Nanog and octamer-binding transcription factor-4, were assessed using western blotting. Intracellular reactive oxygen species (ROS) levels were determined using 2',7'-dichlorodihydrofluorescein diacetate fluorescent probes. Reverse transcription-quantitative PCR and western blotting were used to assess the expression of forkhead box protein M1 (FoxM1), cyclin D1 (CCND1) and matrix metalloproteinase 9 (MMP9). The results indicated that treatment with DDW significantly inhibited the proliferation, tumor-sphere formation, migration and invasion of HT-29 and DLD-1 cells, as well as the expression of stemness-related proteins. In the mechanistic analysis, DDW treatment was revealed to decrease ROS production and downregulate the expression of FoxM1. As the downstream targets of FoxM1, the expression levels of CCND1 and MMP9 were also shown to be decreased. Moreover, H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.